Delcath Systems Reports 210% Revenue Growth and Turns Profit in Q2 2025 Financial Results

Delcath Systems, Inc. (NASDAQ: DCTH) - Q2 2025 Financial Overview

Delcath Systems, Inc., a biopharmaceutical company and leader in the treatment of cancers affecting the liver, has recently released its financial report for the quarter ending June 30, 2025. The company has shown significant progress in its product revenue, primarily driven by its newly launched HEPZATO KIT.

Positive Aspects of Income Statement:

• Product Revenue: Total revenue for Q2 2025 reached $24.156 million, a substantial increase from $7.766 million in Q2 2024.
• Gross Profit: Recorded a gross profit of $20.838 million for Q2 2025, up from $6.247 million year-over-year.
• Operating Income: Achieved operating income of $2.590 million compared to a loss of $3.912 million in Q2 2024.
• Net Income: Reported a net income of $2.697 million in Q2 2025 compared to a loss of $13.741 million in the same period last year.
• Cash Position: As of June 30, 2025, Delcath had cash and cash equivalents totaling $34.4 million, compared to $32.4 million at the end of 2024.

Negative Aspects of Income Statement:

• Operating Expenses: Increased operating expenses totaling $18.248 million for Q2 2025, from $10.159 million in Q2 2024, driven primarily by growth in research and development (R&D) and selling, general and administrative expenses (SG&A).
• R&D Expenses: R&D expenses rose to $6.882 million in Q2 2025 from $3.394 million in Q2 2024, reflecting the costs of expanding clinical trials.
• SG&A Expenses: Increased SG&A expenses to $11.366 million compared to $6.765 million year-over-year, indicating a significant investment in commercial expansion and personnel.

Key Statistics:

• Revenue Growth: 210% increase in total revenue from Q2 2024 to Q2 2025.
• Net Income: $2.697 million for Q2 2025 versus a loss of $13.741 million in Q2 2024.
• Weighted Average Shares Outstanding: 35,786,813 for Q2 2025.
• Interest Income: Gained interest income of $649,000 in Q2 2025 vs. interest expense of $84,000 in Q2 2024.

This financial report illustrates that Delcath Systems is on a promising trajectory with its product launches and revenue growth focusing on liver cancer treatments.